ArticleJournal of thoracic disease2011
Active-specific immunotherapy for non-small cell lung cancer.
Article in Journal of thoracic disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Activation of the IL-4/STAT6 Signaling Pathway Promotes Lung Cancer Progression by Increasing M2 Myeloid Cells.Frontiers in immunology · 2019Article
- Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting.Annals of translational medicine · 2016Review
- TREM-2 serves as a negative immune regulator through Syk pathway in an IL-10 dependent manner in lung cancer.Oncotarget · 2016Article
- Immunotherapy for lung cancer: for whom the bell tolls?Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Actual status of therapeutic vaccination in non-small cell lung cancer.Contemporary oncology (Poznan, Poland) · 2014Review
- Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer.Cancer investigation · 2013Article
- Effect of targeted silencing of hTERT mRNA by lentivirus-mediated siRNA on A549 lung cancer cells in vitro.Molecular biology reports · 2013Article
- Improving lung cancer survival; time to move on.BMC pulmonary medicine · 2012Article
- The efficacy of the inhalation of an aerosolized Group A streptococcal preparation in the treatment of lung cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2012Article
- The therapeutic function of the chemokine RANTES on the H22 hepatoma ascites model.Molecular and cellular biochemistry · 2012Article
- Effects of BTG2 on proliferation inhibition and anti-invasion in human lung cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Article
- Tumor-induced CD8+ T-cell dysfunction in lung cancer patients.Clinical & developmental immunology · 2012Review
- Maintenance treatment with chemotherapy and immunotherapy in non-small cell lung cancer: a case report.Frontiers in oncology · 2012Article
- NSCLC - immunogenic after all?Journal of thoracic disease · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Non-small cell lung cancer constitutes about 85% of all newly diagnosed cases of lung cancer and continues to be the leading cause of cancer-related deaths worldwide. Standard treatment for this devastating disease, such as systemic chemotherapy, has reached a plateau in effectiveness and comes with considerable toxicities. For all stages of disease fewer than 20% of patients are alive 5 years after diagnosis; for metastatic disease the median survival is less than one year. Until now, the success of active-specific immunotherapy for all tumor types has been sporadic and unpredictable. However, the active-specific stimulation of the host's own immune system still holds great promise for achieving non-toxic and durable antitumor responses. Recently, sipuleucel-T (Provenge(®); Dendreon Corp., Seattle, WA) was the first therapeutic cancer vaccine to receive market approval, in this case for advanced prostate cancer. Other phase III clinical trials using time-dependent endpoints, e.g. in melanoma and follicular lymphoma, have recently turned out positive. More sophisticated specific vaccines have now also been developed for lung cancer, which, for long, was not considered an immune-sensitive malignancy. This may explain why advances in active-specific immunotherapy for lung cancer lag behind similar efforts in renal cell cancer, melanoma or prostate cancer. However, various vaccines are now being evaluated in controlled phase III clinical trials, raising hopes that active-specific immunotherapy may become an additional effective therapy for patients with lung cancer. This article reviews the most prominent active-specific immunotherapeutic approaches using protein/peptide, whole tumor cells, and dendritic cells as vaccines for lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.